These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9087504)

  • 1. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans.
    Chin NX; Weitzman I; Della-Latta P
    Antimicrob Agents Chemother; 1997 Apr; 41(4):850-2. PubMed ID: 9087504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans.
    Nash JD; Burgess DS; Talbert RL
    J Med Microbiol; 2002 Feb; 51(2):105-109. PubMed ID: 11863260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Aug; 43(8):3807-10. PubMed ID: 16081915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW; Johnson EM; Rogers TR
    J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced activity of antifungal drugs by lysozyme against Cryptococcus neoformans.
    Nakamura Y; Kano R; Watanabe S; Takahashi H; Hasegawa A
    Mycoses; 1998; 41(5-6):199-202. PubMed ID: 9715633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
    Burgess DS; Hastings RW
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.
    Faria NC; Kim JH; Gonçalves LA; Martins Mde L; Chan KL; Campbell BC
    Lett Appl Microbiol; 2011 May; 52(5):506-13. PubMed ID: 21332761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans.
    Shrestha SK; Grilley M; Anderson T; Dhiman C; Oblad J; Chang CW; Sorensen KN; Takemoto JY
    Med Mycol; 2015 Nov; 53(8):837-44. PubMed ID: 26260746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.
    Barchiesi F; Gallo D; Caselli F; Di Francesco LF; Arzeni D; Giacometti A; Scalise G
    J Antimicrob Chemother; 1999 Jul; 44(1):65-70. PubMed ID: 10459811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.
    Chen SC; O'Donnell ML; Gordon S; Gilbert GL
    J Antimicrob Chemother; 1996 Feb; 37(2):265-73. PubMed ID: 8707736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
    Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
    Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flucytosine primary resistance in Candida species and Cryptococcus neoformans.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):276-9. PubMed ID: 11399020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
    Perfect JR; Cox GM; Dodge RK; Schell WA
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.
    Yotsuji A; Shimizu K; Araki H; Fujimaki K; Nishida N; Hori R; Annen N; Yamamoto S; Hayakawa H; Imaizumi H; Watanbe Y; Narita H
    Antimicrob Agents Chemother; 1997 Jan; 41(1):30-4. PubMed ID: 8980750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
    Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.